Farglitazar

Farglitazar
Clinical data

Pregnancy category	N/A
ATC code	none
Legal status
Legal status	Investigational
Identifiers
IUPAC name N-(o-benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine
CAS Number	196808-45-4^N
PubChem CID	170364
IUPHAR/BPS	2672
ChemSpider	148961^N
UNII	3433GY7132
ChEMBL	CHEMBL107367^N
Chemical and physical data
Formula	C₃₄H₃₀N₂O₅
Molar mass	546.612 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(c1ccccc1)c2ccccc2N[C@H](C(=O)O)Cc5ccc(OCCc3nc(oc3C)c4ccccc4)cc5
InChI InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1^N Key:ZZCHHVUQYRMYLW-HKBQPEDESA-N^N
^NY (what is this?)

Farglitazar is a peroxisome proliferator-activated receptor agonist which is being developed by GlaxoSmithKline for the treatment of hepatic fibrosis. It is currently in phase II clinical trials.